Sanofi’s Dengvaxia: US FDA Panel Finds Pediatric Use More Acceptable Than Broader Target Population

 
• By Sue Sutter
  
FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers